1,490 results on '"Eto, Masatoshi"'
Search Results
2. Papillary renal neoplasm with reverse polarity has low frequency of alterations in chromosomes 7, 17, and Y
3. Clinical practice guidelines for telesurgery 2022: Committee for the promotion of remote surgery implementation, Japan Surgical Society
4. Current status and future perspective of immunotherapy for renal cell carcinoma
5. Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement
6. Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy
7. Field experiment of a telesurgery system using a surgical robot with haptic feedback
8. Functional outcomes in robot-assisted partial nephrectomy with three-dimensional images reconstructed from computed tomography: a propensity score-matched comparative analysis
9. Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project
10. ASO Author Reflections: Treatment Choice for Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy
11. Improved urinary continence recovery after robot-assisted radical prostatectomy with lateral pelvic fascia preservation
12. Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator–activated receptor promotes enzalutamide resistance in prostate cancer
13. Telesurgery and telesurgical support using a double-surgeon cockpit system allowing manipulation from two locations
14. Virtual reality environments to train soft skills in medical and nursing education: a technical feasibility study between France and Japan
15. Reliability, validity, and responsiveness of the Japanese version of the EORTC QLQ-ELD14 in evaluating the health-related quality of life of elderly patients with cancer
16. Steroids-producing nodules: a two-layered adrenocortical nodular structure as a precursor lesion of cortisol-producing adenoma
17. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial
18. Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report
19. Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study
20. Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy
21. Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy
22. Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate
23. 2.5-mm articulated endoluminal forceps using a compliant mechanism
24. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
25. Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer
26. Radical nephroureterectomy for UTUC conferred survival benefits irrespective of age and comorbidities
27. Evaluation of bone density and skeletal muscle mass after sleeve gastrectomy using computed tomography method
28. Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features
29. TFE3-immunopositive papillary renal cell carcinoma: A clinicopathological, immunohistochemical, and genetic study
30. Validation of user-friendly models predicting extracapsular extension in prostate cancer patients
31. Adverse Events of Abiraterone Acetate vs Enzalutamide
32. Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
33. Independent validation of genetic risk model to progression after intravesical bacillus Calmette‐Guérin therapy for non‐muscle invasive bladder cancer
34. Supplementary Tables S1-S5 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma
35. Data from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma
36. Supplementary Legends from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma
37. Supplementary Figure S1 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma
38. Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer
39. Initial experience with vibegron for the treatment of neurogenic lower urinary tract storage dysfunction in patients with spinal cord injury
40. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
41. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
42. Effect of HLA genotype on intravesical recurrence after bacillus Calmette–Guérin therapy for non-muscle-invasive bladder cancer
43. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
44. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma
45. Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine
46. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation
47. HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability
48. Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
49. Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
50. Current status and future perspective on the management of metastatic castration-sensitive prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.